126 related articles for article (PubMed ID: 17908987)
1. Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma.
Gross ND; Boyle JO; Du B; Kekatpure VD; Lantowski A; Thaler HT; Weksler BB; Subbaramaiah K; Dannenberg AJ
Clin Cancer Res; 2007 Oct; 13(19):5910-7. PubMed ID: 17908987
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase.
Ennis BW; Fultz KE; Smith KA; Westwick JK; Zhu D; Boluro-Ajayi M; Bilter GK; Stein B
J Pharmacol Exp Ther; 2005 Apr; 313(1):325-32. PubMed ID: 15626722
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy.
Riedel F; Götte K; Hörmann K; Grandis JR
Adv Otorhinolaryngol; 2005; 62():103-20. PubMed ID: 15608422
[TBL] [Abstract][Full Text] [Related]
4. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.
Bancroft CC; Chen Z; Yeh J; Sunwoo JB; Yeh NT; Jackson S; Jackson C; Van Waes C
Int J Cancer; 2002 Jun; 99(4):538-48. PubMed ID: 11992543
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of basal activity of c-jun-NH2-terminal kinase (JNK) represses the expression of presenilin-1 by a p53-dependent mechanism.
Lee S; Das HK
Brain Res; 2008 May; 1207():19-31. PubMed ID: 18374905
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S
Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin pathway promotes tumor-induced angiogenesis in adenoid cystic carcinoma: its suppression by isoliquiritigenin through dual activation of c-Jun NH2-terminal kinase and inhibition of extracellular signal-regulated kinase.
Sun ZJ; Chen G; Zhang W; Hu X; Huang CF; Wang YF; Jia J; Zhao YF
J Pharmacol Exp Ther; 2010 Aug; 334(2):500-12. PubMed ID: 20484154
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
9. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
Chen Z; Zhang X; Li M; Wang Z; Wieand HS; Grandis JR; Shin DM
Clin Cancer Res; 2004 Sep; 10(17):5930-9. PubMed ID: 15355926
[TBL] [Abstract][Full Text] [Related]
10. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo.
Riedel F; Götte K; Li M; Hörmann K; Grandis JR
Int J Oncol; 2003 Sep; 23(3):577-83. PubMed ID: 12888890
[TBL] [Abstract][Full Text] [Related]
11. A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis.
Leelahavanichkul K; Amornphimoltham P; Molinolo AA; Basile JR; Koontongkaew S; Gutkind JS
Mol Oncol; 2014 Feb; 8(1):105-18. PubMed ID: 24216180
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
Dong G; Chen Z; Li ZY; Yeh NT; Bancroft CC; Van Waes C
Cancer Res; 2001 Aug; 61(15):5911-8. PubMed ID: 11479233
[TBL] [Abstract][Full Text] [Related]
13. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
Huang SM; Harari PM
Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
[TBL] [Abstract][Full Text] [Related]
14. N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells.
Kim HJ; Chakravarti N; Oridate N; Choe C; Claret FX; Lotan R
Oncogene; 2006 May; 25(19):2785-94. PubMed ID: 16407847
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion.
Nozawa H; Howell G; Suzuki S; Zhang Q; Qi Y; Klein-Seetharaman J; Wells A; Grandis JR; Thomas SM
Clin Cancer Res; 2008 Jul; 14(13):4336-44. PubMed ID: 18594017
[TBL] [Abstract][Full Text] [Related]
16. Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.
Badarni M; Prasad M; Balaban N; Zorea J; Yegodayev KM; Joshua BZ; Dinur AB; Grénman R; Rotblat B; Cohen L; Elkabets M
JCI Insight; 2019 Mar; 5(8):. PubMed ID: 30860495
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy.
Li M; Ye C; Feng C; Riedel F; Liu X; Zeng Q; Grandis JR
Clin Cancer Res; 2002 Nov; 8(11):3570-8. PubMed ID: 12429648
[TBL] [Abstract][Full Text] [Related]
18. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of radiation response with the vascular targeting agent ZD6126.
Hoang T; Huang S; Armstrong E; Eickhoff JC; Harari PM
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1458-65. PubMed ID: 16488554
[TBL] [Abstract][Full Text] [Related]
20. c-Jun N-terminal kinase negatively regulates epidermal growth factor-induced cyclooxygenase-2 expression in oral squamous cell carcinoma cell lines.
Husvik C; Bryne M; Halstensen TS
Eur J Oral Sci; 2009 Dec; 117(6):663-8. PubMed ID: 20121928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
